First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Summary
Third Opinion Trial Synopsis:
We are testing a new drug called SAR442257 to see how much patients with relapsed and refractory multiple myeloma and non-Hodgkin lymphoma can handle. We want to find the safe amount of the drug for future testing. We also want to check if the drug is safe and if it works against the cancer.
We are testing a new drug called SAR442257 to see how much patients with relapsed and refractory multiple myeloma and non-Hodgkin lymphoma can handle. We want to find the safe amount of the drug for future testing. We also want to check if the drug is safe and if it works against the cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the pharmacokinetics (PK) profile of SAR442257 To evaluate the potential immunogenicity of SAR442257 To assess preliminary evidence of antitumor activity
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the pharmacokinetics (PK) profile of SAR442257 To evaluate the potential immunogenicity of SAR442257 To assess preliminary evidence of antitumor activity
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: